

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

CONTINUING CONNECTED TRANSACTION COOPERATION AGREEMENT IN RELATION TO NEW ENERGY PROJECTS

The Board is pleased to announce that, on 28 April 2023, CR Sanjiu entered into the Cooperation Agreement with CR Power in relation to the proposed cooperation on the New Energy Projects for a term commencing from the date of the Cooperation Agreement to 31 December 2023.

As at the date of this announcement, CR Holdings, being a controlling shareholder of the Company indirectly holding 53.05% interest in the Company, indirectly holds 62.94% interest in CR Power as at the date of this announcement. Accordingly, CR Power is a connected person of the Company and the Cooperation Agreement and the transactions contemplated thereunder constitute connected transactions for the Company pursuant to Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios as set out in Rule 14.07 of the Listing Rules in respect of the aggregate annual cap for the transactions contemplated under the Cooperation Agreement exceed 0.1% but are less than 5%, the Cooperation Agreement and the transactions and proposed annual cap contemplated thereunder are only subject to reporting, announcement and annual review requirements but are exempted from independent shareholders' approval requirement under Chapter 14A of the Listing Rules.

INTRODUCTION

The Board is pleased to announce that, on 28 April 2023, CR Sanjiu entered into the Cooperation Agreement with CR Power in relation to the proposed cooperation on the New Energy Projects for a term commencing from the date of the Cooperation Agreement to 31 December 2023.

THE COOPERATION AGREEMENT

The principal terms of the Cooperation Agreement are set out as follows:

(1) Date

28 April 2023

(2) Parties

(a) CR Sanjiu, an indirect non-wholly owned subsidiary of the Company; and

(b) CR Power

(3) Term

From 28 April 2023 to 31 December 2023. Subject to compliance with the Listing Rules, listing rules of the Shenzhen Stock Exchange and other applicable laws and regulations, the parties may renew the term of the Cooperation Agreement.

(4) Scope of Transactions under the Cooperation Agreement

Pursuant to the Cooperation Agreement, CR Sanjiu and CR Power have agreed to cooperate with each other on new energy power generation project(s) (the “**New Energy Project(s)**”) in the following manners:

(a) By leveraging their respective strengths, CR Sanjiu and CR Power will be beneficial for the development of their respective businesses.

- (b) CR Power and/or its subsidiaries commissions CR Sanjiu and/or its subsidiaries to develop and provide land remediation services for abandoned land. CR Sanjiu and/or its subsidiaries solve the issue of abandoned land in new energy power projects by planting traditional Chinese medicinal herbs and provide comprehensive land management services to meet the land requirements of the projects.

During the term of the Cooperation Agreement, the parties may enter into specific contracts in respect of specific management services, fees and other requirements for the relevant New Energy Projects in accordance with the principles set forth in the Cooperation Agreement. The terms of such specific contracts shall be negotiated between the parties on arm's length basis and shall be fair and reasonable in accordance with the principles set forth in the Cooperation Agreement, having regard to the actual conditions of the relevant New Energy Projects.

(5) Pricing Basis and Pricing Policies

The service fees payable for the specific services under the Cooperation Agreement shall be determined through arm's length basis by the parties with reference to the then prevailing market price and taking into account various factors, including, but not limited to, the climatic conditions, soil conditions, labour costs and market conditions where the relevant New Energy Project is located, as well as the relevant parties' resources, budgets, experiences, quality assurance requirements and technical requirements.

The Group, similar to other independent third party suppliers, is required to go through the selection and approval procedures by CR Power as well as the commercial negotiation process in order to become its service provider. As part of the Group's internal approval and monitoring procedures relating to transactions with CR Holdings and its associates, the Group also compare the terms that are offered by other independent third parties and/or obtain market or industry data on the pricing of transactions of similar nature, scope and scale from time to time through publicly available information to the extent reasonably practicable, in order to ensure that the transactions are on normal commercial terms, and the transactions will be reviewed and passed by the Group's internal approval procedures. The Group has implemented adequate internal control measures for monitoring all of its continuing connected transactions.

Historical Amounts

Set out below are the approximate historical transaction amounts in relation to cooperation on new energy power generation projects between the Group and CR Power Group for the years ended 31 December 2020, 2021 and 2022:

	For the years ended 31 December					
	2020		2021		2022	
	<i>RMB</i> <i>(million)</i>	<i>HK\$</i> <i>(million)</i>	<i>RMB</i> <i>(million)</i>	<i>HK\$</i> <i>(million)</i>	<i>RMB</i> <i>(million)</i>	<i>HK\$</i> <i>(million)</i>
Transaction amounts in relation to cooperation on new energy power generation projects	0	0	0	0	36.00	42.02

During the preceding 12 months from the date of this announcement, the highest applicable percentage ratio in respect of the actual transaction amounts in relation to cooperation on new energy power generation projects between the Group and CR Power Group is less than 0.1%.

Annual Cap and Basis of Determination

The proposed maximum annual cap for the transactions contemplated under the Cooperation Agreement for the term of the Cooperation Agreement ending 31 December 2023 shall be RMB300 million (approximately HK\$350 million).

In determining the proposed annual caps for the transactions contemplated under the Cooperation Agreement, the Company has taken into account the scope of services contemplated thereunder, the historical transaction amounts in relation to the parties' cooperation on new energy power generation projects of similar nature, the specific plans for developing and undertaking the New Energy Projects (such as the geographical locations where the New Energy Projects are expected to be developed and undertaken), as well as the increase in the anticipated needs for land management services for facilitating and supporting the relevant New Energy Projects in light of the favourable government policies in the PRC.

REASONS FOR AND BENEFITS OF THE COOPERATION AGREEMENT

It is expected the proposed cooperation with CR Power Group in relation to the New Energy Projects will be conducive to improving the Group's layout in the TCM industry, enhancing the Group's core capabilities in the upstream TCM industry chain, and further strengthening the Group's sustainable development capability and market competitiveness in the TCM industry by mastering its production layout and advantageous resources of local Chinese medicinal herbs, which is in line with the Group's development plan in the TCM industry chain in China.

The Board (including the independent non-executive Directors) considered that the Cooperation Agreement was negotiated on an arm's length basis and entered into on normal commercial terms and in the ordinary and usual course of business of the Group, and the relevant terms and proposed annual cap thereunder are fair and reasonable and in the interests of the Company and its shareholders as a whole.

IMPLICATIONS UNDER THE LISTING RULES

As at the date of this announcement, CR Holdings, being a controlling shareholder of the Company indirectly holding 53.05% interest in the Company, indirectly holds 62.94% interest in CR Power as at the date of this announcement. Accordingly, CR Power is a connected person of the Company and the Cooperation Agreement and the transactions contemplated thereunder constitute connected transactions for the Company pursuant to Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios as set out in Rule 14.07 of the Listing Rules in respect of the aggregate annual cap for the transactions contemplated under the Cooperation Agreement exceed 0.1% but are less than 5%, the Cooperation Agreement and the transactions and proposed annual cap contemplated thereunder are only subject to reporting, announcement and annual review requirements but are exempted from independent shareholders' approval requirement under Chapter 14A of the Listing Rules.

None of the Directors had any material interest in the Cooperation Agreement and the transactions (including the relevant annual caps) contemplated thereunder, and none of the Directors has abstained from voting on the relevant Board resolutions approving the Cooperation Agreement and the transactions (including the relevant annual caps) contemplated thereunder.

INFORMATION OF THE PARTIES

CR Power

CR Power Group is principally engaged in the investment, development, operation and management of power plants in the PRC. CR Power is an indirect non-wholly owned subsidiary of CR Holdings, which indirectly holds 62.94% interest in CR Power as at the date of this announcement, and CR Holdings is ultimately beneficially owned by CRC. CRC is beneficially owned by State-owned Assets Supervision and Administration Commission of the State Council of the PRC. The shares of CR Power are listed on the Main Board of the Stock Exchange (stock code: 836).

CR Sanjiu

The core business of CR Sanjiu encompasses research and development, manufacturing and sales of pharmaceutical products and other health-related services. CR Sanjiu is an indirect non-wholly owned subsidiary of the Company, and the shares of CR Sanjiu are listed on the Shenzhen Stock Exchange (stock code: 000999). The Company is indirectly owned as to 53.05% by CR Holdings, which is ultimately beneficially owned by CRC.

The Group

The Group's core business encompasses research and development, manufacturing, distribution and retail of an extensive range of pharmaceutical and other healthcare products.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“associate(s)”	has the meaning ascribed thereto under the Listing Rules;
“Board”	the board of Directors;
“Company”	China Resources Pharmaceutical Group Limited, a company incorporated in Hong Kong with limited liability;
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules;
“controlling shareholder”	has the meaning ascribed thereto under the Listing Rules;
“Cooperation Agreement”	the cooperation agreement dated 28 April 2023 entered into between CR Sanjiu and CR Power in relation to the proposed cooperation on the New Energy Projects;
“CR Holdings”	China Resources (Holdings) Company Limited (華潤(集團)有限公司), a company incorporated in Hong Kong with limited liability and a controlling shareholder of the Company;
“CR Power”	China Resources Power Holdings Company Limited (華潤電力控股有限公司), a company incorporated in Hong Kong with limited liability, the shares of which are listed and traded on the Main Board of the Stock Exchange (stock code: 836) and an indirect non-wholly owned subsidiary of CR Holdings as at the date of this announcement;
“CR Power Group”	CR Power and its subsidiaries;

“CR Sanjiu”	China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司), a company incorporated in the PRC, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000999) and an indirect non-wholly owned subsidiary of the Company;
“CR Sanjiu Group”	CR Sanjiu and its subsidiaries;
“CRC”	China Resources Company Limited* (中國華潤有限公司), a company incorporated in the PRC with limited liability;
“Director(s)”	the director(s) of the Company;
“Group”	the Company and its subsidiaries;
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong;
“Hong Kong”	Hong Kong Special Administrative Region of the PRC;
“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange;
“New Energy Project(s)”	the new energy project(s) contemplated under the Cooperation Agreement, the details of which are set forth in the section “The Cooperation Agreement – (4) Scope of Transactions under the Cooperation Agreement” in this announcement;
“PRC” or “China”	the People’s Republic of China, for the purpose of this announcement only, excluding Hong Kong, Macau Special Administrative Region of the PRC and Taiwan;
“RMB”	Renminbi, the lawful currency of the PRC;

“Stock Exchange” The Stock Exchange of Hong Kong Limited;

“subsidiary(ies)” has the meaning ascribed thereto under the Listing Rules.

For the purpose of this announcement and illustration only, conversions of RMB into HK\$ are based on the approximate exchange rate of RMB1.00 to HK\$1.16726. No representation is made that any amount in HK\$ or RMB could have been or could be converted at the above rate or at any other rates.

For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese version shall prevail.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Beijing, 28 April 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.